Skip to main content

NCT02407223 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis


CSR Summary

Not yet available


Primary Citation

Trial has yet to be published


Data Specification

Not Available


Annotated CRF

Not Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Ustekinumab
Product Name
STELARA®
Therapeutic Area
Muscle, Bone, and Cartilage Diseases
Enrollment
356
% Female
N/A
% White
N/A
Product Class
mAB anti-IL12 and anti-IL23
Sponsor Protocol Number
CNTO1275AKS3003
Data Holder
Johnson & Johnson
Condition Studied
Spondylitis, Ankylosing (Nonradiographic Axial)
Mean/Median Age (Years)
N/A

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Data Definition Specification
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.